Centering on the Needs of Diagnosis and Treatment and Focusing on the Creators
Wuhan Ammunition Life Technology Co., Ltd.( abbreviated as "Ammunition" ) , is a high-tech enterprise focusing on non-invasive screening and early detection products development and testing services for high incident malignant tumors worldwide. Ammunition has a complete system for the IVD R & D, manufacturing, marketing, and medical testing.
With the concept of "early, accurate, non-invasive, home-based", the company has developed a series of early non-invasive screening products for cancers of high incidence (ICON®series). Ammunition’s massion is to decrease the incidence and mortality of cancer in China and reduce overall medical costs through the integration of early screening products and testing services.
To eradicate more than 80% of tumors by early diagnosis and treatment, to reduce medical costs by 50%, so as to alleviate the poverty caused by cancer.
Through extracting and detecting fecal DNA, IColocomf® can be used to find precancerous lesions and early colorectal cancer five years earlier. It can find progressive adenoma with the diameter larger than 1cm, so as to block the cancer in the pre or early stage.Learn more
Leading medical science and technology to achieve health monument
Early tumor lesions
The detection rate is higher than 90%
Highly specific to tumor
The specificity was higher than 90%
Non invasive detection
The compliance of patients is high
Self sampling at home
High privacy without need to go out of home
Building a high tech Enterprise
Latest news and Industry information
28, March 2021 Day, the first large national offline merchants conference exclusively hosted by emison life technologies, Wuhan, will be held at International Expo Center Room n1-m202, this offline merchants conference relies on the 18th China International Expo sure to Laboratory Medicine & transfusion instruments reagent (referred to as "caclp") as a background to establish a company brand and promote the company's products as a core, inviting well-known experts for academic speakingLoci and market prospects analysis.
Recently, Wuhan Ammunition Life Technology Co., Ltd.(abbreviated as "Ammunition") announced the completion of nearly billion yuan b-round financing, which was being invested by Jin He capital, an investment institution that deepens the field of medical health, innovative investment in Yangtze River Securities, and follow-up by old shareholder hybribio (300639) in this round.Previously, the company was also awarded Silver medical growth fund, hybribio A round, PREA round investments, respectively.It is noted that this round of financing will assist the registration report, expansion of the R & D pipeline, and focus on advancing the market and commercialization of products for early detection of tumor in Wuhan.
According to the relevant regulations of the Ministry of science and Technology (State Academy of science and technology  No. 32) and the guide for the identification and management of high and technology enterprises (State Academy of science and technology  No. 195), Wuhan Ammunition Life Technology Co., Ltd.(abbreviated as "Ammunition") by virtue of a professional R & D team, excellent technological strength, continuous innovative ability and scientific enterprise management, successfully passes through a highNew technology enterprise identification.